Nancy J. Sullivan, ScD
Edward Avedisian Professor
Boston University

ScD, Harvard University
MS, Harvard University
BS, Merrimack College

Dr. Nancy Sullivan is the Director of the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University. She assumed the role in December of 2022, a pivotal time of heightened global awareness of the threats posed by emerging infectious diseases. While building on its outstanding record of research, she intends to steer NEIDL into the space where basic scientific discovery, translational research, pandemic preparedness, and global engagement meet.

An internationally respected leader in viral immunology, emerging diseases prevention, and infectious disease research, Dr. Sullivan previously served as chief of the Biodefense Research Section at the Vaccine Research Center (VRC) in the National Institutes of Health’s National Institute of Allergy and Infectious Disease (NIAID). She was a member of the NIAID’s Pandemic Preparedness Working Group where she proposed the protoptype pathogen approach to vaccine development [i] that is now in widespread use by national and international organizations. Dr. Sullivan was also deeply involved in the US response to COVID-19. During the pandemic, she coauthored close to 40 COVID-related research papers, covering topics as diverse as vaccine and therapeutics development and tracking of SARS-CoV-2 variant resistance to neutralization.

Beyond her work on COVID-19, Dr. Sullivan has a long-standing commitment to the study of emerging pathogens with pandemic potential including, mpox, Nipah, Ebola, Marburg, and other high consequence viruses. The global importance of her work became dramatically clear in the spring of 2014 with the multi-country outbreak of the deadly Ebola disease in West Africa. Based on years of prior research developing gene-based approaches to Ebola vaccines, Dr. Sullivan and her team were first to demonstrate vaccine protection against Ebola infection in primates, leading to development of the ChAd3-Ebola vaccine that was deployed for efficacy testing during the 2013-2016 outbreak.

Dr. Sullivan has received numerous citations for these achievements. She was named among “The Ebola Fighters” whom Time magazine awarded its Person of the Year in 2014; and in 2015, she was included in Politico’s Top 50, again for her work on Ebola. She has also received multiple NIH Director’s Awards, NIH Staff Recognition Awards, and NIAID Merit Awards, and she was a Service Service to America Medals finalist.

Modeling the role in public life she expects the NEIDL to play, Dr. Sullivan has taken her fight against emerging infectious diseases (EID) well outside her own lab. Her team developed vaccines against Marburg and Sudan viruses that have advanced to Phase I/II human clinical trials and are currently being developed by the Sabin Vaccines Institute. She also formed partnerships in the Democratic Republic of Congo (DRC) and led the discovery from a DRC Ebola survivor of a potently protective therapeutic monoclonal antibody, mAb114, that is effective in saving the lives of nearly 90% of Ebola patients who are treated soon after they contract the disease. In December of 2020, mAb114, became the NIH Vaccine Research Center’s first FDA-approved clinical product, and it is now marketed as Ebanga.

Alongside these scientific breakthroughs, Dr. Sullivan founded a scientific research and capacity building training program that is preparing scientists in the DRC to develop and fund their own independent, regionally appropriate research programs. By several years, this work anticipated global efforts of organizations like the WHO to decentralize and, at the same time, coordinate EID research.

Dr. Sullivan is a native of the Boston area. She earned her undergraduate degree at Merrimack College and doctorate at Harvard T. H. Chan School of Public Health. In 2023, Boston University appointed her the Edward Avedisian Professor and Professor of Virology, Immunology & Microbiology at the Chobanian & Avedisian School of Medicine and Professor of Biology in the College of Arts and Sciences.

Boston University
National Emerging Infectious Disease Lab

Boston University Chobanian & Avedisian School of Medicine
Virology, Immunology & Microbiology

Boston University College of Arts and Sciences

National Emerging Infectious Diseases Laboratories Operations
07/08/2021 - 06/30/2026 (PI)
NIH/National Institute of Allergy & Infectious Diseases

Determine the Efficacy of Obeldesivir, the Oral Remdesivir Prodrug, to Mitigate od Treat Illness Caused by Nipah Virs Infection - Non-GLP
03/08/2024 - 07/31/2025 (Subcontract PI)
Battelle Memorial Institute JPEO-CBRND

Multispecific mAbs characterization - RCVSV Resistance Assay
04/01/2024 - 03/31/2025 (PI)
ModeX Therapeutics, Inc.


Yr Title Project-Sub Proj Pubs
2023 Ebola Vaccine Development 1ZIAAI005079-19
2023 Marburg Vaccine Development 1ZIAAI005080-19
2023 Ebola Vaccine Immune Correlates and Mechanism of Protection 1ZIAAI005082-19
2023 mAbs and vaccines against SARS CoV-2 1ZIAAI005145-04
2023 Monkeypox vaccines and monoclonal antibodies 1ZIAAI005167-02
2023 Nipah virus vaccines and monoclonal antibodies 1ZIAAI005168-02
2022 Monkeypox vaccines and monoclonal antibodies 1ZIAAI005167-01
2022 Marburg Vaccine Development 1ZIAAI005080-18
2022 Yeast Engineering Technology & Immunobiology Core 1ZIAAI005142-04
2022 mAbs and vaccines against SARS CoV-2 1ZIAAI005145-03
Showing 10 of 81 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, Amuri-Aziza A, Malyamungu-Bubala N, Mweshi-Kumbana F, Mutimbwa-Mambo L, Belesi-Siangoli F, Mujula Y, Parker E, Muswamba-Kayembe PC, Nundu SS, Lushima RS, Makangara-Cigolo JC, Mulopo-Mukanya N, Pukuta-Simbu E, Akil-Bandali P, Kavunga H, Abdramane O, Brosius I, Bangwen E, Vercauteren K, Sam-Agudu NA, Mills EJ, Tshiani-Mbaya O, Hoff NA, Rimoin AW, Hensley LE, Kindrachuk J, Baxter C, de Oliveira T, Ayouba A, Peeters M, Delaporte E, Ahuka-Mundeke S, Mohr EL, Sullivan NJ, Muyembe-Tamfum JJ, Nachega JB, Rambaut A, Liesenborghs L, Mbala-Kingebeni P. Sustained Human Outbreak of a New MPXV Clade I Lineage in the Eastern Democratic Republic of the Congo. Nat Med. 2024 Jun 13. PMID: 38871006
  2. Nachega JB, Sam-Agudu NA, Ogoina D, Mbala-Kingebeni P, Ntoumi F, Nakouné E, Njouom R, Lewis RF, Gandhi M, Rosenthal PJ, Rawat A, Wilson LA, Kindrachuk J, Liesenborghs L, Mills EJ, Preiser W, Rimoin AW, Sullivan NJ, Peeters M, Delaporte E, Baxter C, Harrison L, Hermans MP, Mohr EL, Gonsalves G, Ndembi N, Zumla A, Muyembe-Tamfum JJ. The surge of mpox in Africa: a call for action. Lancet Glob Health. 2024 Jul; 12(7):e1086-e1088. PMID: 38735300
  3. Happe M, Hofstetter AR, Wang J, Yamshchikov GV, Holman LA, Novik L, Strom L, Kiweewa F, Wakabi S, Millard M, Kelley CF, Kabbani S, Edupuganti S, Beck A, Kaltovich F, Murray T, Tsukerman S, Carr D, Ashman C, Stanley DA, Ploquin A, Bailer RT, Schwartz R, Cham F, Tindikahwa A, Hu Z, Gordon IJ, Rouphael N, Houser KV, Coates EE, Graham BS, Koup RA, Mascola JR, Sullivan NJ, Robb ML, Ake JA, Lyke KE, Mulligan MJ, Ledgerwood JE, Kibuuka H. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials. NPJ Vaccines. 2024 Mar 29; 9(1):67. PMID: 38553525; PMCID: PMC10980745; DOI: 10.1038/s41541-024-00833-z;
  4. Honko AN, Hunegnaw R, Moliva JI, Ploquin A, Dulan CNM, Murray T, Carr D, Foulds KE, Geisbert JB, Geisbert TW, Johnson JC, Wollen-Roberts SE, Trefry JC, Stanley DA, Sullivan NJ. A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure. bioRxiv. 2024 Feb 12.View Related Profiles. PMID: 38410448; PMCID: PMC10896339; DOI: 10.1101/2024.02.07.579118;
  5. Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc Natl Acad Sci U S A. 2024 Feb 13; 121(7):e2316960121.View Related Profiles. PMID: 38319964; PMCID: PMC10873634; DOI: 10.1073/pnas.2316960121;
  6. Sankhala RS, Lal KG, Jensen JL, Dussupt V, Mendez-Rivera L, Bai H, Wieczorek L, Mayer SV, Zemil M, Wagner DA, Townsley SM, Hajduczki A, Chang WC, Chen WH, Donofrio GC, Jian N, King HAD, Lorang CG, Martinez EJ, Rees PA, Peterson CE, Schmidt F, Hart TJ, Duso DK, Kummer LW, Casey SP, Williams JK, Kannan S, Slike BM, Smith L, Swafford I, Thomas PV, Tran U, Currier JR, Bolton DL, Davidson E, Doranz BJ, Hatziioannou T, Bieniasz PD, Paquin-Proulx D, Reiley WW, Rolland M, Sullivan NJ, Vasan S, Collins ND, Modjarrad K, Gromowski GD, Polonis VR, Michael NL, Krebs SJ, Joyce MG. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques. Nat Commun. 2024 Jan 03; 15(1):200. PMID: 38172512; PMCID: PMC10764318; DOI: 10.1038/s41467-023-44265-0;
  7. Moliva JI, Andrew SF, Flynn BJ, Wagner DA, Foulds KE, Gagne M, Flebbe DR, Lamb E, Provost S, Marquez J, Mychalowych A, Lorag CG, Honeycutt CC, Burnett MR, McCormick L, Henry AR, Godbole S, Davis-Gardner ME, Minai M, Bock KW, Nagata BM, Todd JM, McCarthy E, Dodson A, Kouneski K, Cook A, Pessaint L, Ry AV, Valentin D, Young S, Littman Y, Boon ACM, Suthar MS, Lewis MG, Andersen H, Alves DA, Woodward R, Leuzzi A, Vitelli A, Colloca S, Folgori A, Raggiolli A, Capone S, Nason MC, Douek DC, Roederer M, Seder RA, Sullivan NJ. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates. bioRxiv. 2023 Nov 22. PMID: 38076895; PMCID: PMC10705562; DOI: 10.1101/2023.11.22.567930;
  8. Dupuy LC, Spiropoulou CF, Towner JS, Spengler JR, Sullivan NJ, Montgomery JM. Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation. J Infect Dis. 2023 Oct 18; 228(Suppl 6):S446-S459. PMID: 37849404; PMCID: PMC11009505; DOI: 10.1093/infdis/jiad362;
  9. Xu D, Powell AE, Utz A, Sanyal M, Do J, Patten JJ, Moliva JI, Sullivan NJ, Davey RA, Kim PS. Design of universal Ebola virus vaccine candidates via immunofocusing. bioRxiv. 2023 Oct 17.View Related Profiles. PMID: 37904982; PMCID: PMC10614775; DOI: 10.1101/2023.10.14.562364;
  10. Freyn AW, Atyeo C, Earl PL, Americo JL, Chuang GY, Natarajan H, Frey TR, Gall JG, Moliva JI, Hunegnaw R, Asthagiri Arunkumar G, Ogega CO, Nasir A, Santos G, Levin RH, Meni A, Jorquera PA, Bennett H, Johnson JA, Durney MA, Stewart-Jones G, Hooper JW, Colpitts TM, Alter G, Sullivan NJ, Carfi A, Moss B. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci Transl Med. 2023 Oct 04; 15(716):eadg3540. PMID: 37792954
Showing 10 of 155 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 155 publications over 32 distinct years, with a maximum of 24 publications in 2021


2022 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2020 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission,
2020 National Institutes of Health,: Special Act Award
2020 Service to America Medals: People’s Choice Award (Finalist)
2019 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
2019 Science Magazine: Breakthrough of the Year (top ten nominated)
2018 National Institute of Allergy and Infectious Diseases, Vaccine Research Center: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
2018 Office of Technology Transfer, National Institutes of Health: Philip S. Chen Distinguished Lecture on Innovation and Technology Transfer
2017 Merrimack College: Honorary Doctorate
2016 Federal Laboratory Consortium for Technology Transfer (FLC): Excellence in Technology Transfer Award
2015 National Institutes of Health: NIH Director’s Award
2015 Politico Magazine: The Politico Top 50
2014 TIME: Time Person of the Year: Ebola Fighters, Time Magazine, for Research on Ebola virus vaccines
2011 National Institute of Allergy and Infectious Diseases,: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
Contact for Mentoring:

620 Albany St
Boston MA 02118
Google Map

Sullivan's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department